Resources

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.

Just one month after launch, five early-stage science companies have moved into the Leap incubator lab space at ARC West London. The first cohort of innovators joining Leap includes: Solveteq, Reseda Life Sciences, Tachmed, IgEDAPT, and Sea2Carbon.

London Life Sciences Week kicked off last night with a buzzing reception at Somerset House and we’re looking forward to a jam-packed week of networking and events. Great to see the incredible hard work from the BIA and L&P teams come to life – shining a global light on the incredible UK ecosystem. At the same time, we’re seeing the UK take a leading role in pro-innovation regulation, from last week’s enactment of the Precision Breeding Act to Lawrence Tallon’s insights on the MHRA’s proportionate, strategic future approach, and now need the government to invest in the sector and ensure the commercial environment enables the UK to build on this world-beating foundation.

Kirsty Neilson, Programme Manager at IBioIC, explains why she has just launched a new programme – Biotech Innovators: Train to Scale – offering a specialist business support programme for budding bioentrepreneurs.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, shares insights from the BIA's first-of-its-kind funding and investment analysis into UK Deep Biotech.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.

The BioIndustry Association (BIA) has today published a report highlighting the rapid growth of the UK’s Deep Biotech sector.

In a world of uncertainty, Britain’s biotech future looks strong.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.

Imperial, the leading global science university, is achieving a major step up in its life sciences capacity at its White City Deep Tech Campus through a major new joint venture with Bruntwood SciTech.

Read today's blog to learn about our latest reports, upcoming events and our CEO's thoughts on the upcoming budget.

In this blog, Izzy Webb outlines why the UK has published voluntary guidance to promote DNA synthesis and who the guidance is intended for.